EP1063989A1 - Prevention and treatment of adhesions - Google Patents
Prevention and treatment of adhesionsInfo
- Publication number
- EP1063989A1 EP1063989A1 EP99910880A EP99910880A EP1063989A1 EP 1063989 A1 EP1063989 A1 EP 1063989A1 EP 99910880 A EP99910880 A EP 99910880A EP 99910880 A EP99910880 A EP 99910880A EP 1063989 A1 EP1063989 A1 EP 1063989A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- active agent
- synthesis
- secretion
- plasminogen activator
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 230000002265 prevention Effects 0.000 title description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 71
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 57
- 239000013543 active substance Substances 0.000 claims abstract description 53
- 210000005033 mesothelial cell Anatomy 0.000 claims abstract description 33
- 230000028327 secretion Effects 0.000 claims abstract description 31
- 230000001965 increasing effect Effects 0.000 claims abstract description 23
- 241000282414 Homo sapiens Species 0.000 claims abstract description 20
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 230000003247 decreasing effect Effects 0.000 claims abstract description 17
- 210000000056 organ Anatomy 0.000 claims abstract description 17
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims abstract description 15
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims abstract description 15
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims abstract description 15
- 102000001938 Plasminogen Activators Human genes 0.000 claims abstract description 13
- 108010001014 Plasminogen Activators Proteins 0.000 claims abstract description 13
- 229940127126 plasminogen activator Drugs 0.000 claims abstract description 13
- RZPAXNJLEKLXNO-UHFFFAOYSA-N (20R,22R)-3beta,22-Dihydroxylcholest-5-en Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C(O)CCC(C)C)C1(C)CC2 RZPAXNJLEKLXNO-UHFFFAOYSA-N 0.000 claims abstract description 12
- RZPAXNJLEKLXNO-GFKLAVDKSA-N (22R)-22-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)[C@H](O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-GFKLAVDKSA-N 0.000 claims abstract description 12
- OJISWRZIEWCUBN-QIRCYJPOSA-N (E,E,E)-geranylgeraniol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO OJISWRZIEWCUBN-QIRCYJPOSA-N 0.000 claims abstract description 11
- XWRJRXQNOHXIOX-UHFFFAOYSA-N geranylgeraniol Natural products CC(C)=CCCC(C)=CCOCC=C(C)CCC=C(C)C XWRJRXQNOHXIOX-UHFFFAOYSA-N 0.000 claims abstract description 11
- OJISWRZIEWCUBN-UHFFFAOYSA-N geranylnerol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO OJISWRZIEWCUBN-UHFFFAOYSA-N 0.000 claims abstract description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 3
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 3
- 229960001727 tretinoin Drugs 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 41
- 102000004311 liver X receptors Human genes 0.000 claims description 29
- 108090000865 liver X receptors Proteins 0.000 claims description 29
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 21
- 229960002855 simvastatin Drugs 0.000 claims description 21
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 21
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims description 17
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 17
- 238000001356 surgical procedure Methods 0.000 claims description 15
- 239000003527 fibrinolytic agent Substances 0.000 claims description 9
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 7
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 7
- 230000003480 fibrinolytic effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 229960004844 lovastatin Drugs 0.000 claims description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000000116 mitigating effect Effects 0.000 claims description 3
- 210000000115 thoracic cavity Anatomy 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 abstract description 31
- 239000000203 mixture Substances 0.000 abstract description 15
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 abstract 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 48
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 48
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000003636 conditioned culture medium Substances 0.000 description 12
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 8
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 7
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 7
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 7
- 108091027981 Response element Proteins 0.000 description 7
- 229930182558 Sterol Natural products 0.000 description 7
- 229960001445 alitretinoin Drugs 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 150000003432 sterols Chemical class 0.000 description 7
- 235000003702 sterols Nutrition 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000003094 microcapsule Substances 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 102000034527 Retinoid X Receptors Human genes 0.000 description 5
- 108010038912 Retinoid X Receptors Proteins 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010023197 Streptokinase Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960005202 streptokinase Drugs 0.000 description 4
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical group CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 102000016978 Orphan receptors Human genes 0.000 description 3
- 108070000031 Orphan receptors Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- MCKLJFJEQRYRQT-APGJSSKUSA-N 20-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@](C)(O)CCCC(C)C)[C@@]1(C)CC2 MCKLJFJEQRYRQT-APGJSSKUSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 206010034650 Peritoneal adhesions Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- LCTONWCANYUPML-YZRHJBSPSA-N (1-14c)pyruvate Chemical compound CC(=O)[14C](O)=O LCTONWCANYUPML-YZRHJBSPSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IXRAQYMAEVFORF-UTLNTRLCSA-N (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IXRAQYMAEVFORF-UTLNTRLCSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- YIKKMWSQVKJCOP-ABXCMAEBSA-N 7-ketocholesterol Chemical compound C1C[C@H](O)CC2=CC(=O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]3[C@]21C YIKKMWSQVKJCOP-ABXCMAEBSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- QTBSBXVTEAMEQO-HQMMCQRPSA-N acetic acid Chemical compound C[14C](O)=O QTBSBXVTEAMEQO-HQMMCQRPSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004189 ion pair high performance liquid chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- -1 oxysterols Chemical compound 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 108091008672 sterol hormone receptors Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to medical treatments to prevent or reduce the occurrence of adhesions to and between body organs, parts of body organs and/or tissues in animals, in particular human beings, such as the adhesions occurring after surgical procedures .
- intraperitoneal adhesions after abdominal surgery or peritoneal inflammation is a common cause of intestinal obstruction and impaired fertility in women, and can be a complicating factor in subsequent operations.
- sequence of events leading to intraperitoneal adhesions and peritoneal fibrosis is thought to start with fibrin deposition followed by immigration and proliferation of fibroblasts and collagen synthesis by fibroblasts.
- the fibrin deposits are the result of an imbalance between the pro- coagulant (fibrin- forming) and the fibrinolytic (fibrin- dissolving) activities of the peritoneum.
- Adhesions may also occur after surgery of other body cavities, such as thorax or heart, and may occur after inflammatory processes in such cavities, such as seen with, for example, peritonitis, pericarditis and pleuritis.
- quinacrine hydrochloride U.S. Patent No. 5,478,837
- corticosteroids non-steroidal anti- inflammatory drugs
- anticoagulants such as heparin (Jansen, Surg . Gynecol . Obstet . 166 , 154, 1988)
- ibuprofen U.S. Patent No. 4,346,108
- antihistamines antibiotics, dextran solutions, polyvinylpyrrolidone solutions and fibrinolytic agents (U.S. Patent No. 5,364,622) .
- fibrinolytic agents such as tissue-type plasminogen activator (t-PA) , urokinase-type plasminogen activator (u-PA) and streptokinase, which appeared to be effective in animal models, results have so far been disappointing.
- These fibrinolytic agents convert the inactive zymogen plasminogen into plasmin. Plasmin effects the degradation of fibrin. Since fibrin deposition is a critical factor in the development of adhesions, administration of t-PA, u-PA or streptokinase results in the prevention of adhesion formation or removal of adhesions already formed.
- Mesothelial cells are the major cell population involved in the lining of the peritoneal cavity. It has been shown that cultured human mesothelial cells (HMC) produce t- PA and u-PA, and that the activity of these plasminogen activators in the medium is counteracted by the concomitant secretion of specific plasminogen activator inhibitors, including plasminogen activator inhibitor-1 (PAI-1).
- HMC human mesothelial cells
- PAI-1 plasminogen activator inhibitor-1
- the invention provides a method for reducing or preventing adhesions to or between organs, parts of organs or tissues, at a particular location, in an animal, comprising subjecting said animal to a treatment which provides for increased synthesis and/or secretion of plasminogen activator or for decreased synthesis and/or secretion of plasminogen activator inhibitor (PAI) by mesothelial cells present at said location.
- a treatment which provides for increased synthesis and/or secretion of plasminogen activator or for decreased synthesis and/or secretion of plasminogen activator inhibitor (PAI) by mesothelial cells present at said location.
- PAI plasminogen activator inhibitor
- the invention provides a method to increase endogenous fibrinolytic capacity at said location, for example a body cavity, in a regulated way during a desired period of time, instead of administration of exogenous t-PA, u-PA or streptokinase.
- Applying a method according to the invention thus prevents or reduces the deposition of fibrin (one of the primary steps in the sequence of events leading to adhesions) by increasing the endogenous (of the body itself; in vivo) production of tissue-type plasminogen activator.
- said animal is a mammal, most preferably a human being, and said location is or has been, or may become, exposed to trauma, which might lead to local fibrosis.
- the invention finds its use in veterinary practice, for example in small or large animal practice where birds, or mammalians or other vertebrate animals are treated.
- the invention finds its use in medicine.
- An example of trauma is a surgical procedure, e.g. abdominal or thoracic surgery.
- Another example is trauma after accidents, where for example internal bleeding is stopped by treatment with coagulants. After such a treatment with coagulants, the invention finds its use in helping prevent adhesions.
- the invention provides a method wherein said treatment comprises administration to said animal of an active agent capable of increasing t-PA and/or u-PA synthesis and/or secretion or for decreasing synthesis and/or secretion of PAI-1 by said mesothelial cells.
- Said treatment comprises application of said active agent, preferably at said location after a risk for the occurrence of adhesions has been observed, but systemic or parenteral treatment is also possible, and such treatments may also be given as a preventive measure, for example shortly before a surgical treatment is being contemplated or going to be executed.
- the invention provides a method wherein said active agent is capable of enhancing t-PA synthesis or decreasing PAI-1 synthesis by mesothelial cells.
- Examples of such an active agent can be found m the group composed of vastatins such as simvastatm, lovastatm, mevmolme, distinct oxysterols such as 22 (R) - hydroxycholesterol .
- Use of retmoids such as all-trans retmoic acid and 9-c ⁇ s retmoic acid m combination with such an active agent increases the t-PA synthesis or decreases PAI-1 synthesis by mesothelial cells..
- the invention provides a method wherein said active agent is capable of inhibiting HMG-CoA reductase, thereby increasing t-PA and/or u-PA synthesis and/or secretion by mesothelial cells, and/or thereby decreasing synthesis and/or secretion of PAI-1 by these cells.
- Mevalonic acid (MVA) constitutes the key metabolite m the biosynthesis of isoprenoids, which are the precursors of sterols (e.g. cholesterol and oxysterols) and a variety of non-sterol derivatives such as farnesyl- and geranylgeranyl-pyrophosphate (GGPP) .
- HMG-CoA reductase inhibitors of which (vastatins such as simvastatin, lovastatin, mevinoline) are widely used as anti-atherosclerotic drugs in patients with hypercholesteremia .
- Other agents capable of acting synergistically with HMG-CoA reductase inhibitors are for example distinct natural oxysterols and 9-cis retinoic acid.
- HMG-CoA reductase strongly increases t-PA synthesis in mesothelial cells, while decreasing PAI-1.
- simvastatin treatment of such cells strongly increases t-PA synthesis, which, in a second aspect, is further potentiated by subsequent or co-administration of 9-cis retinoic acid and/or 22 (R) -hydroxycholesterol , or combinations thereof.
- the invention also provides a method which counteracts any of above said methods of treatment which provide for increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells.
- the invention thus not only provides a method to increase the endogenous fibrinolytic capacity of for example a cavity in a regulated way but also provides a method to increase said capacity for a derived period of time. In cases where one wishes to actively stop or mitigate any of above said treatments, it may be not enough to simply stop said treatment and wait till the effects dwindle down.
- a second treatment, with an active agent capable of counteracting the first treatment is provided by the invention.
- the invention for example provides an effective method to counteract the effect seen after treatment with HMG-CoA reductase inhibitors such as simvastatin, lovastatin, or mevinoline or for example with distinct oxysterols and retinoic acid, by, for example subsequent or concomitant, administration of for example MVA or geranylgeraniol , which quench or counteract a plasminogen activator increase or PAI decrease.
- HMG-CoA reductase inhibitors such as simvastatin, lovastatin, or mevinoline or for example with distinct oxysterols and retinoic acid
- the invention also provides use of an active agent capable of providing for increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells, for preparing a pharmaceutical composition for reducing or preventing adhesions to or between organs, parts of organs or tissues.
- a preferred embodiment of the invention is wherein said mesothelial cells are mammalian, for example human .
- said active agent is capable of enhancing synthesis and/or secretion of plasminogen activator, preferably of t-PA, by said mesothelial cells.
- said active agent is capable of decreasing synthesis and/or secretion of plasminogen activator inhibitor, preferably of PAI-1, by said mesothelial cells.
- said active agent is selected from the group composed of vastatins such as simvastatin, lovastatin, mevinoline, distinct oxysterols such as 22 (R) -hydroxycholesterol , and 9-cis retinoic acid.
- said active agent is selected from the group consisting of inhibitors of mevalonic acid synthesis such as simvastatin or a functional equivalent thereof, inhibitors of geranylgeraniol synthesis or oxysterols such as 22 (R) -hydroxycholesterol or functional equivalents thereof .
- said active agent is selected from agents or compositions capable of inhibiting HMG-CoA reductase or from agents or compositions capable of activating liver-X-receptor or related receptors.
- Liver-X-receptor is an orphan receptor that displays constitutive transcriptional activity.
- naturally occurring oxysterols such as 20 (S) -hydroxycholesterol ((OH-Chol), 22 (R) -OH-Chol, 24 (S) -OH-Chol and 24 (S) , 25-epoxy-Chol , but not other products of mevalonate metabolism, activate LXR at concentrations consistent with 7
- GG-PP another metabolite of MVA
- GG-PP is a strong inhibitor of LXR.
- a software- based search of the t-PA promoter for a binding site for LXR led to the identification of a putative response element at position -8,682: ACTGGG taac ACTTGG (motif DR4/inv) .
- the invention also provides use of an active agent capable of counteracting increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells, for preparing a pharmaceutical composition for counteracting or mitigating the action of any of the above described pharmaceutical compositions for reducing or preventing adhesions to or between organs, parts of organs or tissues, said active agent preferably being MVA or geranylgeraniol .
- compositions and methods according to the present invention are useful in reducing, minimising or preventing adhesion formation, the most common cause of which is prior surgery.
- the compositions and methods according to the present invention have been shown to be especially effective in preventing the formation of adhesions between organ surfaces, in particular adhesion formation in the peritoneum following surgery.
- the present invention also finds utility in other contexts, however, such as e.g. for cardiovascular, orthopaedic, thoracic, ophthalmic, central nervous system and other uses where prevention of the formation of adhesions after surgery, or during or after inflammatory processes is a significant concern.
- attention is directed primarily to a description of compositions and methods useful in inhibiting peritoneal adhesion formation, but the various possibilities and preferred embodiments disclosed therein apply to all other conditions where the invention is applicable.
- composition as used herein is intended to cover both the active agent alone and a composition containing the active agent together with a pharmaceutically acceptable carrier, diluent or excipient .
- an active agent is administered in an effective concentration at the site of potential adhesion formation.
- the administration may be done as a single dose, as a discontinuous sequence of various doses, or continuously for a period of time sufficient to permit substantial tissue repair, in particular re-epithelisation or mesothelial repair.
- the active agent is typically administered during the surgical procedure up to some time after completion thereof, and administration may even be carried out or initiated shortly before surgery.
- the duration of the administration may vary depending upon a number of factors which would readily be appreciated by those skilled in the art.
- a composition in accordance with the present invention should be effected from the time of surgery for at least one or two days after completion of the surgical procedure. As healing is in most cases complete within about two_ weeks, it is generally not necessary to continue administration of a composition in accordance with the present invention much longer than two weeks.
- a composition according to the present invention is administered from about the time of surgery for a period of about one day to about two weeks, such as more particularly for a period of about two days to about one week.
- the administration dose of the active agent may be varied over a fairly broad range.
- concentrations of an active agent which can be administered would be limited by efficacy at the lower end and the solubility of the compound at the upper end.
- the optimal dose or doses for a particular patient should and can be determined by the physician or medical specialist involved, taking into consideration well known relevant factors such as the condition, weight and age of the patient, the given or predicted extent of the adhesions, etc.
- the active agent may be administered directly in a suitable vehicle, such as e.g. phosphate-buffered saline (PBS) or as solutions in alcohol or DMSO .
- a suitable vehicle such as e.g. phosphate-buffered saline (PBS) or as solutions in alcohol or DMSO .
- PBS phosphate-buffered saline
- the active agent is administered through a single dose delivery using a drug-delivery system, such as a sustained-release delivery system, which enables the maintenance of the required concentrations of the active agent for a period of time sufficient for adequate tissue repair.
- a suitable drug- delivery system would be pharmacologically inactive or at least tolerable. It should preferably not be immunogenic nor cause inflammatory reactions, and should permit release of the active agent so as to maintain effective levels thereof over the desired time period.
- Suitable delivery vehicles include, but are not limited to, the following: microcapsules or microspheres; liposomes and other lipid-based release systems; viscous instillates; absorbable and/or biodegradable mechanical barriers and implants; and polymeric delivery materials, such as polyethylene oxide/polypropylene oxide block copolymers, polyesters, cross-linked polyvinylalcohols, polyanhydrides , polymethacrylate and polymethacrylamide hydrogels, anionic carbohydrate polymers, etc. useful delivery systems are well known in the art.
- a highly suitable formulation to achieve the active agent release comprises injectable microcapsules or microspheres made from a biodegradable polymer, such as poly (dl-lactide) , poly (dl-lactide-co-glycolide) , polycaprolactone, polyglycolide , polylactic acid-co- glycolide, poly (hydroxybutyric acid), polyesters or polyacetals.
- injectable systems comprising microcapsules or microspheres having a diameter of about 50 to about 10
- 500 micrometers offer advantages over other delivery systems. For example, they generally use less active agent and may be administered by paramedical personnel. Moreover, such systems are inherently flexible in the design of the duration and rate of separate drug release by selection of microcapsule or microsphere size, drug loading and dosage administered. Further, they can be successfully sterilised by gamma irradiation.
- microcapsules and microspheres are well within the reach of persons skilled in the art and detailed information concerning these points is available in the literature.
- Biodegradable polymers such as lactide, glycolide and caprolactone polymers
- Fibres or filaments comprising the active agent are also contemplated as within the scope of the present invention.
- Another highly suitable formulation for a single-dose delivery of the active agent in accordance with the present invention involves liposomes.
- Suitable approach for single dose delivery of an active agent in accordance with the present invention involves the use of viscous installates.
- high molecular weight carriers are used in admixture with the active agent, giving rise to a structure which produces a solution with high viscosity.
- Suitable high molecular weight carriers include, but are not limited to, the following: dextrans and cyclodextrans ; hydrogels; (cross- linked) viscous materials, including (cross-linked) 11
- the active agent may be administered in combination with absorbable mechanical barriers such oxidised regenerated cellulose.
- the active agent may be covalent or non-covalently (e.g. ionically) bound to such a barrier, or it may simply be dispersed therein.
- Fig. 1 Human mesothelial cells were incubated for 24 hours at 37°C with vehicle only (control) or 1 ⁇ mol/L simvastatin, 10 ⁇ mol/L mevalonate, 10 ⁇ mol/L geranylgeraniol or combinations thereof. The conditioned media were analysed for t-PA antigen. The data shown are from one representative experiment performed in triplicate and are expressed as mean values .
- Fig. 3 Human endothelial cells were incubated for 24 hours at 37°C with vehicle only (control) or 1 ⁇ mol/L simvastatin, 10 ⁇ mol/L 9-cis retinoic acid. The conditioned media were analysed for PAI-1 antigen. The data shown are from one representative experiments performed in triplicate and are expressed as mean values.
- Fig. 4 Human mesothelial cells and human endothelial cells were incubated for 24 hours at 37°C with vehicle only (control) or 1 ⁇ mol/L simvastatin, 10 ⁇ mol/L 9-cis retinoic acid, 10 ⁇ mol/L 22 (R) -hydroxycholesterol , or combinations thereof. The conditioned media were analysed for t-PA antigen. The data shown are from one representative experiment performed in triplicate and are expressed as mean values .
- t-PA synthesis in HMC is both positively and negatively regulated by distinct products of mevaronic acid metabolism.
- mevaronic acid metabolism we were able to increase endogenous t-PA production by HMC.
- the addition of certain oxysterols further increased this stimulated t-PA expression, whereas the administration of geranylgeraniol, another metabolite of mevalonic acid, suppressed the elevated t-PA expression observed in HMC with diminished mevalonic acid biosynthesis. Comparable results were obtained with other t-PA producing cells, including human vascular endothelial cells.
- mevalonic acid metabolites such as certain oxysterols and/or inhibitors of mevalonic acid synthesis or the formation of certain mevalonic acid metabolites such as geranylgeraniol provides the possibility to increase the endogenous fibrinolytic capacity of human mesothelial cells and other t-PA-producing cells where such an increased capacity is desirable. 13
- HMC human peritoneal mesothelial cells
- HEC human endothelial cells
- Cells were grown m fib ⁇ nonectin-coated dishes m M199 supplemented with 20 mmol/L HEPES (pH 7,4), 10% (vol/vol), human serum, 10% (vol/vol) heat -inactivated newborn calf serum, 150 ⁇ g/mL endothelial cell growth supplement, 2 mmol/L L-glutamme, 5 IU/mL hepa ⁇ n, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin at 37 °C m a 5%
- MVA mevalonate pathway
- MVA metabolism yields a series of isoprenoids that serve as precursors to a large number of important molecules, including cholesterol, oxysterols, farnesyl -pyrophosphate (F-PP) and geranylgeranyl- pyrophosphate (GG-PP) .
- F-PP farnesyl -pyrophosphate
- GG-PP geranylgeranyl- pyrophosphate
- t-PA synthesis in HMC is positively and negatively regulated by distinct products of MVA metabolism.
- Our experiments indicate that these effects are likely to be mediated via a recently discovered orphan member of the nuclear hormone receptor superfamily, such as liver-X- receptor (LXR) .
- LXR liver-X- receptor
- Inhibition of endogenous MVA synthesis in HMC strongly increased t-PA gene expression.
- Addition of specific oxysterols, shown to activate LXR increased t-PA expression under basal conditions and further increased the stimulated t-PA expression seen in MVA-deprived HMC. 3.
- t-PA contains such a specific response element (see below) .
- t-PA and LXR The activation profile of t-PA and LXR clearly differs from that of related receptors such as the farnesol-X-receptor (Cell 8JL, 687-693, 1995) and sterol receptors described by Goldstein and Brown (Cell 8_9, 331-340, 1997) .
- Cell 8JL farnesol-X-receptor
- sterol receptors described by Goldstein and Brown
- Ox-LDL oxidised low-density lipoprotein
- HEC cultured humn endothelial cells
- Ox-LDL Ox-LDL-derived oxysterols
- oxysterols notably 25 (R) -hydroxycholesterol and 7-ketocholesterol
- oxysterols notably 25 (R) -hydroxycholesterol and 7-ketocholesterol
- other, naturally occurring, intra-cellularly formed oxystereols such as 22 (R) -hydroxycholesterol specifically stimulate t-PA synthesis in HMC.
- precursors along the main pathway to cholesterol synthesis both positively and negatively regulate t-PA and PAI-1 synthesis in HMC.
- cholesterol derivatives including steroid hormones and vitamin D
- members of the nuclear receptor superfamily function as ligand-activated transcription factors by binding to short stretches of DNA, termed hormone response elements, present in the regulatory regions of target genes.
- this superfamily comprises a large number of structurally related members that contain DNA binding domains and putative ligand binding 17
- Liver-X-receptor is an orphan receptor that displays constitutive transcriptional activity.
- Naturally occurring oxysterols such as 20 (S) -hydroxycholesterol ((OH-Chol), 22 (R) -OH-Chol, 24 (S) -OH-Chol and 24 (S) , 25-epoxy-Chol , but not other products of mevalonate metabolism, activated LXR at concentrations consistent with those found in tissue extracts.
- GG-PP another metabolite of MVA, was a strong inhibitor of LXR.
- LXR binds as a heterodimer with the retinoid-X-receptor (RXR) to DENA response elements that are direct repeats of the core sequence AG(G/T) TCA spaced by four nucleotides, a so-called DR-4 motif.
- RXR retinoid-X-receptor
- the sequence is part of a 2.4 kb DNA fragment, located 7.1 kb upstream relative to the start site of transcription, which acts as a multi-hormone enhancer.
- the pathway intermediates are subsequently separated and quantified by reversed-phase ion-pair HPLC by examining the incorporation of [ 14 C] pyruvate, [ 14 C] mevalonate or [ 3 H] -isopentenyl- pyrophosphate as precursors. Identification is primarily on the basis of established retention times. The addition of internal standards at the beginning of the extraction procedure allows the correction of any variability in recovery of the radio- labelled intermediates between experiments or between individual samples. The procedure is readily adaptable to cultured human endothelial cells.
- t-PA, u-PA, PAI-1 are measured to obtain information regarding the intracellular metabolic processes 19
- the isoprenoid balance and the expression of markers of mesothelial functioning. Antigen measurements are performed using routine methods such as ELISA.
- Example 1 One way to increase t-PA synthesis by mesothelial cells is to prevent the mtracellular synthesis of mevalonic acid (MVA) from 3-hydroxy-3 -methylglutaryl coenzyme A (HMG-CoA) , for example, by the administration of simvastatin, an inhibitor of HMG-CoA reductase (Goldstein and Brown, Nature 343, 425, 1990) .
- MVA mevalonic acid
- HMG-CoA 3-hydroxy-3 -methylglutaryl coenzyme A
- Example 2 We measured t-PA antigen accumulation m the conditioned media of mesothelial cells after 24 hours incubation the presence of simvastatin (1 ⁇ mol/L) , 22 (R) -hydroxycholesterol (10 ⁇ mol) or a combination thereof (Fig. 2) . Both compounds increased t-PA antigen production and, when added together, showed at least additive effects.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to medical treatments and compositions to prevent or reduce the occurrence of adhesions to and between body organs, parts of body organs and/or tissues in animals, in particular human beings, such as the adhesions occurring after surgical proccedures. The invention provides for reducing or preventing adhesions to or between organs, parts of organs or tissues, at a particular location, in an animal, comprising subjecting said animal to a treatment which provides for increased synthesis and/or secretion of plasminogen activator by mesothelial cells present at said location, or to a treatment which provides for decreased synthesis and/or secretion of plasminogen activator inhibitor by mesothelial cells present at said location. The active agents are selelcted form the group composed of vastatins or distinct natural oxysterols, such as 22 (R)-hydroxycholesterol, mevalonate, or geranylgeraniol or combinations thereof, optionally combined with retinoic acid.
Description
Title: Prevention and treatment of adhesions
Field of the invention
The present invention relates to medical treatments to prevent or reduce the occurrence of adhesions to and between body organs, parts of body organs and/or tissues in animals, in particular human beings, such as the adhesions occurring after surgical procedures .
Background of the invention
The occurrence of intraperitoneal adhesions after abdominal surgery or peritoneal inflammation is a common cause of intestinal obstruction and impaired fertility in women, and can be a complicating factor in subsequent operations. Although not all etiological aspects are known, the sequence of events leading to intraperitoneal adhesions and peritoneal fibrosis is thought to start with fibrin deposition followed by immigration and proliferation of fibroblasts and collagen synthesis by fibroblasts. The fibrin deposits are the result of an imbalance between the pro- coagulant (fibrin- forming) and the fibrinolytic (fibrin- dissolving) activities of the peritoneum. Adhesions may also occur after surgery of other body cavities, such as thorax or heart, and may occur after inflammatory processes in such cavities, such as seen with, for example, peritonitis, pericarditis and pleuritis.
It has been reasoned that the restoration of the balance at an early stage of the disease process might lead to diminished fibrin deposition and thus might retard or prevent the fibroblast response and, consequently, adhesion formation.
To prevent adhesions of peritoneal surfaces, various pharmacological agents have been investigated or proposed, including quinacrine hydrochloride (U.S. Patent No. 5,478,837), corticosteroids , non-steroidal anti- inflammatory
drugs (Holz, Fertil . Steril . 37, 582, 1982), anticoagulants such as heparin (Jansen, Surg . Gynecol . Obstet . 166 , 154, 1988), ibuprofen (U.S. Patent No. 4,346,108), antihistamines , antibiotics, dextran solutions, polyvinylpyrrolidone solutions and fibrinolytic agents (U.S. Patent No. 5,364,622) .
With the exception of the fibrinolytic agents such as tissue-type plasminogen activator (t-PA) , urokinase-type plasminogen activator (u-PA) and streptokinase, which appeared to be effective in animal models, results have so far been disappointing. These fibrinolytic agents convert the inactive zymogen plasminogen into plasmin. Plasmin effects the degradation of fibrin. Since fibrin deposition is a critical factor in the development of adhesions, administration of t-PA, u-PA or streptokinase results in the prevention of adhesion formation or removal of adhesions already formed.
This concept proved to be effective in the prevention of experimentally- induced peritoneal adhesions in animals, incl. rats (Evans et al . , Am. J. Surg. 165, 229, 1993; Hill- West et al . , J. Surg. Res. 5_9, 759, 1995), rabbits (Doody et al . , Fertil. Steril. 5_1, 509, 1989; Menzies and Ellis, J. Royal. Soc . Med. 8_2, 534, 1989; Menzies and Ellis, Surg. Gynecol. Obstet. 172 , 362, 1991; Dorr et al . , Eur . J. Obstet. Gynecol. Reprod. Biol . 3_7, 287, 1990; Orita et al . , Int. J. Fertil. 3.6, 172, 1991; Dunn and Mohler, J. Surg. Res. 5_4, 242, 1993) and dogs (Am. J. Obstet. Gynecol. 165, 1539, 1991) .
Limitations and drawbacks of the administration of fibrinolysis activators are the relatively large amounts required, a transient time of action due to leakage from the cavity to plasma (Flessner et al . , Am. J. Physiol . 240 , H15,
1985) or inhibition by specific inhibitors, and, in the case of streptokinase, the evoked immune response. An attractive alternative would be to increase the endogenous fibrinolytic capacity of a cavity in a regulated
3
way during a desired period of time, but no effective strategies have been described up till now.
Mesothelial cells are the major cell population involved in the lining of the peritoneal cavity. It has been shown that cultured human mesothelial cells (HMC) produce t- PA and u-PA, and that the activity of these plasminogen activators in the medium is counteracted by the concomitant secretion of specific plasminogen activator inhibitors, including plasminogen activator inhibitor-1 (PAI-1).
Summary of the invention
The invention provides a method for reducing or preventing adhesions to or between organs, parts of organs or tissues, at a particular location, in an animal, comprising subjecting said animal to a treatment which provides for increased synthesis and/or secretion of plasminogen activator or for decreased synthesis and/or secretion of plasminogen activator inhibitor (PAI) by mesothelial cells present at said location. Herewith, the invention provides a method to increase endogenous fibrinolytic capacity at said location, for example a body cavity, in a regulated way during a desired period of time, instead of administration of exogenous t-PA, u-PA or streptokinase. Applying a method according to the invention thus prevents or reduces the deposition of fibrin (one of the primary steps in the sequence of events leading to adhesions) by increasing the endogenous (of the body itself; in vivo) production of tissue-type plasminogen activator.
Preferably, said animal is a mammal, most preferably a human being, and said location is or has been, or may become, exposed to trauma, which might lead to local fibrosis. In animals, the invention finds its use in veterinary practice, for example in small or large animal practice where birds, or mammalians or other vertebrate animals are treated. In humans, the invention finds its use in medicine. An example of trauma is a surgical procedure,
e.g. abdominal or thoracic surgery. Another example is trauma after accidents, where for example internal bleeding is stopped by treatment with coagulants. After such a treatment with coagulants, the invention finds its use in helping prevent adhesions.
In a preferred embodiment, the invention provides a method wherein said treatment comprises administration to said animal of an active agent capable of increasing t-PA and/or u-PA synthesis and/or secretion or for decreasing synthesis and/or secretion of PAI-1 by said mesothelial cells. Said treatment comprises application of said active agent, preferably at said location after a risk for the occurrence of adhesions has been observed, but systemic or parenteral treatment is also possible, and such treatments may also be given as a preventive measure, for example shortly before a surgical treatment is being contemplated or going to be executed. As an example, the invention provides a method wherein said active agent is capable of enhancing t-PA synthesis or decreasing PAI-1 synthesis by mesothelial cells. Examples of such an active agent can be found m the group composed of vastatins such as simvastatm, lovastatm, mevmolme, distinct oxysterols such as 22 (R) - hydroxycholesterol . Use of retmoids such as all-trans retmoic acid and 9-cιs retmoic acid m combination with such an active agent increases the t-PA synthesis or decreases PAI-1 synthesis by mesothelial cells..
In another preferred embodiment, the invention provides a method wherein said active agent is capable of inhibiting HMG-CoA reductase, thereby increasing t-PA and/or u-PA synthesis and/or secretion by mesothelial cells, and/or thereby decreasing synthesis and/or secretion of PAI-1 by these cells. Mevalonic acid (MVA) constitutes the key metabolite m the biosynthesis of isoprenoids, which are the precursors of sterols (e.g. cholesterol and oxysterols) and a variety of non-sterol derivatives such as farnesyl- and geranylgeranyl-pyrophosphate (GGPP) . The production of MVA is
catalysed by HMG-CoA reductase, inhibitors of which (vastatins such as simvastatin, lovastatin, mevinoline) are widely used as anti-atherosclerotic drugs in patients with hypercholesteremia . Other agents capable of acting synergistically with HMG-CoA reductase inhibitors (thereby increasing t-PA synthesis and/or secretion or decreasing synthesis and/or secretion of PAI) are for example distinct natural oxysterols and 9-cis retinoic acid.
Inhibition of HMG-CoA reductase strongly increases t-PA synthesis in mesothelial cells, while decreasing PAI-1. For example, simvastatin treatment of such cells strongly increases t-PA synthesis, which, in a second aspect, is further potentiated by subsequent or co-administration of 9-cis retinoic acid and/or 22 (R) -hydroxycholesterol , or combinations thereof.
The invention also provides a method which counteracts any of above said methods of treatment which provide for increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells. The invention thus not only provides a method to increase the endogenous fibrinolytic capacity of for example a cavity in a regulated way but also provides a method to increase said capacity for a derived period of time. In cases where one wishes to actively stop or mitigate any of above said treatments, it may be not enough to simply stop said treatment and wait till the effects dwindle down. A second treatment, with an active agent capable of counteracting the first treatment is provided by the invention. The invention for example provides an effective method to counteract the effect seen after treatment with HMG-CoA reductase inhibitors such as simvastatin, lovastatin, or mevinoline or for example with distinct oxysterols and retinoic acid, by, for example subsequent or concomitant, administration of for example MVA or geranylgeraniol , which quench or counteract a plasminogen activator increase or PAI decrease.
The invention also provides use of an active agent capable of providing for increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells, for preparing a pharmaceutical composition for reducing or preventing adhesions to or between organs, parts of organs or tissues. A preferred embodiment of the invention is wherein said mesothelial cells are mammalian, for example human . In one embodiment of the invention it is preferred that said active agent is capable of enhancing synthesis and/or secretion of plasminogen activator, preferably of t-PA, by said mesothelial cells. In yet another embodiment of the invention it is preferred that said active agent is capable of decreasing synthesis and/or secretion of plasminogen activator inhibitor, preferably of PAI-1, by said mesothelial cells. According to preferred embodiments, said active agent is selected from the group composed of vastatins such as simvastatin, lovastatin, mevinoline, distinct oxysterols such as 22 (R) -hydroxycholesterol , and 9-cis retinoic acid. Preferably, said active agent is selected from the group consisting of inhibitors of mevalonic acid synthesis such as simvastatin or a functional equivalent thereof, inhibitors of geranylgeraniol synthesis or oxysterols such as 22 (R) -hydroxycholesterol or functional equivalents thereof .
In another embodiment, said active agent is selected from agents or compositions capable of inhibiting HMG-CoA reductase or from agents or compositions capable of activating liver-X-receptor or related receptors.
Liver-X-receptor (LXR) is an orphan receptor that displays constitutive transcriptional activity. For example, naturally occurring oxysterols such as 20 (S) -hydroxycholesterol ((OH-Chol), 22 (R) -OH-Chol, 24 (S) -OH-Chol and 24 (S) , 25-epoxy-Chol , but not other products of mevalonate metabolism, activate LXR at concentrations consistent with
7
those found in tissue extracts. In contrast, GG-PP, another metabolite of MVA, is a strong inhibitor of LXR. A software- based search of the t-PA promoter for a binding site for LXR led to the identification of a putative response element at position -8,682: ACTGGG taac ACTTGG (motif DR4/inv) .
The invention also provides use of an active agent capable of counteracting increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells, for preparing a pharmaceutical composition for counteracting or mitigating the action of any of the above described pharmaceutical compositions for reducing or preventing adhesions to or between organs, parts of organs or tissues, said active agent preferably being MVA or geranylgeraniol .
The compositions and methods according to the present invention are useful in reducing, minimising or preventing adhesion formation, the most common cause of which is prior surgery. The compositions and methods according to the present invention have been shown to be especially effective in preventing the formation of adhesions between organ surfaces, in particular adhesion formation in the peritoneum following surgery. The present invention also finds utility in other contexts, however, such as e.g. for cardiovascular, orthopaedic, thoracic, ophthalmic, central nervous system and other uses where prevention of the formation of adhesions after surgery, or during or after inflammatory processes is a significant concern. In the following discussion, attention is directed primarily to a description of compositions and methods useful in inhibiting peritoneal adhesion formation, but the various possibilities and preferred embodiments disclosed therein apply to all other conditions where the invention is applicable.
The term "pharmaceutical composition" as used herein is intended to cover both the active agent alone and a
composition containing the active agent together with a pharmaceutically acceptable carrier, diluent or excipient .
Pursuant to one embodiment of the present invention, an active agent is administered in an effective concentration at the site of potential adhesion formation. The administration may be done as a single dose, as a discontinuous sequence of various doses, or continuously for a period of time sufficient to permit substantial tissue repair, in particular re-epithelisation or mesothelial repair. The active agent is typically administered during the surgical procedure up to some time after completion thereof, and administration may even be carried out or initiated shortly before surgery. In the case of a continuous administration, the duration of the administration may vary depending upon a number of factors which would readily be appreciated by those skilled in the art. In general, the administration of a composition in accordance with the present invention should be effected from the time of surgery for at least one or two days after completion of the surgical procedure. As healing is in most cases complete within about two_ weeks, it is generally not necessary to continue administration of a composition in accordance with the present invention much longer than two weeks. Preferably, a composition according to the present invention is administered from about the time of surgery for a period of about one day to about two weeks, such as more particularly for a period of about two days to about one week.
The administration dose of the active agent may be varied over a fairly broad range. The concentrations of an active agent which can be administered would be limited by efficacy at the lower end and the solubility of the compound at the upper end. The optimal dose or doses for a particular patient should and can be determined by the physician or medical specialist involved, taking into consideration well known relevant factors such as the condition, weight and age
of the patient, the given or predicted extent of the adhesions, etc.
The active agent may be administered directly in a suitable vehicle, such as e.g. phosphate-buffered saline (PBS) or as solutions in alcohol or DMSO . Pursuant to preferred embodiments of the present invention, however, the active agent is administered through a single dose delivery using a drug-delivery system, such as a sustained-release delivery system, which enables the maintenance of the required concentrations of the active agent for a period of time sufficient for adequate tissue repair. A suitable drug- delivery system would be pharmacologically inactive or at least tolerable. It should preferably not be immunogenic nor cause inflammatory reactions, and should permit release of the active agent so as to maintain effective levels thereof over the desired time period. A large variety of alternatives are known in the art as suitable for purposes of sustained release and are contemplated as within the scope of the present invention. Suitable delivery vehicles include, but are not limited to, the following: microcapsules or microspheres; liposomes and other lipid-based release systems; viscous instillates; absorbable and/or biodegradable mechanical barriers and implants; and polymeric delivery materials, such as polyethylene oxide/polypropylene oxide block copolymers, polyesters, cross-linked polyvinylalcohols, polyanhydrides , polymethacrylate and polymethacrylamide hydrogels, anionic carbohydrate polymers, etc. useful delivery systems are well known in the art.
A highly suitable formulation to achieve the active agent release comprises injectable microcapsules or microspheres made from a biodegradable polymer, such as poly (dl-lactide) , poly (dl-lactide-co-glycolide) , polycaprolactone, polyglycolide , polylactic acid-co- glycolide, poly (hydroxybutyric acid), polyesters or polyacetals. Injectable systems comprising microcapsules or microspheres having a diameter of about 50 to about
10
500 micrometers offer advantages over other delivery systems. For example, they generally use less active agent and may be administered by paramedical personnel. Moreover, such systems are inherently flexible in the design of the duration and rate of separate drug release by selection of microcapsule or microsphere size, drug loading and dosage administered. Further, they can be successfully sterilised by gamma irradiation.
The design, preparation and use of microcapsules and microspheres are well within the reach of persons skilled in the art and detailed information concerning these points is available in the literature. Biodegradable polymers (such as lactide, glycolide and caprolactone polymers) may also be used in formulations other than microcapsules and microspheres; e.g. pre-made films and spray-on films of these polymers containing the active agent would be suitable for use in accordance with the present invention. Fibres or filaments comprising the active agent are also contemplated as within the scope of the present invention. Another highly suitable formulation for a single-dose delivery of the active agent in accordance with the present invention involves liposomes. The encapsulation of an active agent in liposomes or multilamellar vesicles is a well known technique for targeted drug delivery and prolonged drug residence. The preparation and use of drug-loaded liposomes is well within the reach of persons skilled in the art and well documented in the literature.
Yet another suitable approach for single dose delivery of an active agent in accordance with the present invention involves the use of viscous installates. In this technique, high molecular weight carriers are used in admixture with the active agent, giving rise to a structure which produces a solution with high viscosity. Suitable high molecular weight carriers include, but are not limited to, the following: dextrans and cyclodextrans ; hydrogels; (cross- linked) viscous materials, including (cross-linked)
11
viscoelastics ; carboxymethylcellulose ; hyaluronic acid; and chondroitin sulfate. The preparation and use of drug-loaded viscous instillates is well known to persons skilled in the art . Pursuant to yet another approach, the active agent may be administered in combination with absorbable mechanical barriers such oxidised regenerated cellulose. The active agent may be covalent or non-covalently (e.g. ionically) bound to such a barrier, or it may simply be dispersed therein.
The above described approaches for administration apply in general to any active agent in accordance with the present invention. It, however, may be preferred to treat or prevent the occurrence of adhesions with compositions that are delivered via a sustained-release delivery system, whereas counteracting or mitigating such a treatment may preferably be achieved via administration of compositions that release the active agent rapidly, and thus allow immediate action.
Brief description of the drawings
Fig. 1. Human mesothelial cells were incubated for 24 hours at 37°C with vehicle only (control) or 1 μmol/L simvastatin, 10 μmol/L mevalonate, 10 μmol/L geranylgeraniol or combinations thereof. The conditioned media were analysed for t-PA antigen. The data shown are from one representative experiment performed in triplicate and are expressed as mean values .
Fig. 2. Human mesothelial cells were incubated for
24 hours at 37°C with vehicle only (control) or 1 μmol/L simvastatin, 10 μmol/L 22 (R) -hydroxycholesterol , or combinations thereof. The conditioned media were analysed for t-PA antigen. The data shown are from one representative experiment performed in triplicate and are expressed as mean values .
12
Fig. 3. Human endothelial cells were incubated for 24 hours at 37°C with vehicle only (control) or 1 μmol/L simvastatin, 10 μmol/L 9-cis retinoic acid. The conditioned media were analysed for PAI-1 antigen. The data shown are from one representative experiments performed in triplicate and are expressed as mean values.
Fig. 4. Human mesothelial cells and human endothelial cells were incubated for 24 hours at 37°C with vehicle only (control) or 1 μmol/L simvastatin, 10 μmol/L 9-cis retinoic acid, 10 μmol/L 22 (R) -hydroxycholesterol , or combinations thereof. The conditioned media were analysed for t-PA antigen. The data shown are from one representative experiment performed in triplicate and are expressed as mean values .
Experimental part
We have discovered that t-PA synthesis in HMC is both positively and negatively regulated by distinct products of mevaronic acid metabolism. By inhibiting endogenous mevalonic acid synthesis, we were able to increase endogenous t-PA production by HMC. The addition of certain oxysterols further increased this stimulated t-PA expression, whereas the administration of geranylgeraniol, another metabolite of mevalonic acid, suppressed the elevated t-PA expression observed in HMC with diminished mevalonic acid biosynthesis. Comparable results were obtained with other t-PA producing cells, including human vascular endothelial cells.
The use of specific mevalonic acid metabolites such as certain oxysterols and/or inhibitors of mevalonic acid synthesis or the formation of certain mevalonic acid metabolites such as geranylgeraniol provides the possibility to increase the endogenous fibrinolytic capacity of human mesothelial cells and other t-PA-producing cells where such an increased capacity is desirable.
13
Multiple studies were performed to demonstrate that blocking of mevalonate biosynthesis and/or addition of 22 (R) -hydroxycholesterol leads to increases m the levels of t-PA m the conditioned media of mesothelial cells (MC) or endothelial cells (EC) . The model systems used consisted of cultured human peritoneal mesothelial cells (HMC) which were isolated from the omental tissue of consenting patients undergoing elective surgery and of cultured human endothelial cells (HEC) which were isolated from human umbilical cord veins. Cells were grown m fibπnonectin-coated dishes m M199 supplemented with 20 mmol/L HEPES (pH 7,4), 10% (vol/vol), human serum, 10% (vol/vol) heat -inactivated newborn calf serum, 150 μg/mL endothelial cell growth supplement, 2 mmol/L L-glutamme, 5 IU/mL hepaπn, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C m a 5%
C02/95% air atmosphere. The medium was replaced every 2 to 3 days. Subcultures were obtained by trypsm/EDTA treatment of confluent monolayers at a split ratio of 1:3. Cells from omental tissue were pure mesothelial cells as assessed by their uniform cobblestone appearance at confluence, by the absence of von Willebrand factor, and the uniform positive staining for cytokeratms 8 and 18 and for vimentm (van Hmsbergh et al . , Blood 7j5, 1490, 1990). Cells from umbilical cord veins were pure endothelial cells as assessed by their uniform cobblestone appearance at confluence and the uniform positive staining for von Willebrand factor (Jaffe et al . , J. Clin. Invest. 5_2., 2745, 1973 Van Hmsbergh et al . , Arteriosclerosis 3_, 547, 1983) . For the experiments, confluent cultures were used at the second or third passage, and cells were always re-fed the day before the experiment with incubation medium: M199, supplemented with 20 mmol/L HEPES (pH 7.4), 10% (vol/vol) human serum, 2 mmol/L- glutamme, and antibiotics. Conditioned media were obtained by incubating cells m 2 cm2 dishes at 37°C with 0.5 mL incubation medium containing the appropriate concentration of the test compound or stock solvent. The conditioned media
14
were centrifuged for 5 minutes at 8,000 rpm in a Microfuge centrifuge to remove cells and cellular debris. Conditioned media were stored at -20°C until use.
Analysis of metabolites of the mevalonate (MVA) pathway MVA is a common metabolite used by virtually all eukaryotic cells. MVA metabolism yields a series of isoprenoids that serve as precursors to a large number of important molecules, including cholesterol, oxysterols, farnesyl -pyrophosphate (F-PP) and geranylgeranyl- pyrophosphate (GG-PP) . We have established procedures for thin-layer chromatography- and HPLC-based analysis and quantification of intermediates of the MVA pathway and oxysterols (i.e. hydroxylated derivates of cholesterol) from cells that have been administered radiolabelled precursors such as [14C] acetate or [14C] MVA. Interestingly, we have found that t-PA synthesis in HMC is positively and negatively regulated by distinct products of MVA metabolism. Our experiments indicate that these effects are likely to be mediated via a recently discovered orphan member of the nuclear hormone receptor superfamily, such as liver-X- receptor (LXR) . Conditions that stimulate or quench the transactivation activity of LXR in an artificial model system, proved to evoke parallel changes in t-PA expression in our HMC. 1. Inhibition of endogenous MVA synthesis in HMC strongly increased t-PA gene expression. 2. Addition of specific oxysterols, shown to activate LXR, increased t-PA expression under basal conditions and further increased the stimulated t-PA expression seen in MVA-deprived HMC. 3. The effect of oxysterols (ligands for LXR) was potentiated by 9- cis retinoic acid, a ligand for retinoid-X-receptor (RXR) which is the heterodimer partner of LXR. 4. The administration of geranylgeraniol, another metabolite of MVA, suppressed the elevated t-PA expression in MVA-deprived HMC, whereas farnesol was without effect. 5. LXR-RXR heterodimers bind to specific nucleotide sequences, response elements,
15
only present in target genes; t-PA contains such a specific response element (see below) .
The activation profile of t-PA and LXR clearly differs from that of related receptors such as the farnesol-X-receptor (Cell 8JL, 687-693, 1995) and sterol receptors described by Goldstein and Brown (Cell 8_9, 331-340, 1997) . Of interest is also our finding that inhibition of endogenous MVA synthesis in HMC suppressed significantly PAI-1 synthesis, indicating that MVA metabolites have a more general effect on endothelial functioning than merely changing t-PA synthesis.
16
Oxysterols and fibrinolysis
It should be noted that the specific group of oxygenated cholesterol derivatives ('oxysterols") that activate transcription of target genes through the nuclear receptor LXR (see below) differ clearly from the atherogenic oxysterols present in oxidised low-density lipoprotein (Ox-LDL) , and which are auto-oxidation products of cholesterol. Ox-LDL, an atherogenic lipoprotein that exists in atherosclerotic vessel walls, has been shown to stimulate PAI-1 production while it inhibits t-PA release from cultured humn endothelial cells (HEC) . These effects of Ox-LDL could be mimicked by certain oxysterols, notably 25 (R) -hydroxycholesterol and 7-ketocholesterol , which are formed during oxidation of LDL . In contrast to the Ox-LDL-derived oxysterols, we have found that other, naturally occurring, intra-cellularly formed oxystereols such as 22 (R) -hydroxycholesterol specifically stimulate t-PA synthesis in HMC. Also, we observed that precursors along the main pathway to cholesterol synthesis both positively and negatively regulate t-PA and PAI-1 synthesis in HMC. These results suggest a novel interplay between intermediates of cholesterol biosynthesis and metabolites thereof on the one hand and mesothelial functioning on the other hand.
Nuclear hormone receptors and LXR
- A variety of cholesterol derivatives, including steroid hormones and vitamin D, exert effects on gene expression through interactions with members of the nuclear receptor superfamily. Members of this family function as ligand-activated transcription factors by binding to short stretches of DNA, termed hormone response elements, present in the regulatory regions of target genes. In addition to the nuclear receptors with known ligands, this superfamily comprises a large number of structurally related members that contain DNA binding domains and putative ligand binding
17
domains, but lack identified ligands, the so-called "orphan receptors". Liver-X-receptor (LXR) is an orphan receptor that displays constitutive transcriptional activity. Naturally occurring oxysterols such as 20 (S) -hydroxycholesterol ((OH-Chol), 22 (R) -OH-Chol, 24 (S) -OH-Chol and 24 (S) , 25-epoxy-Chol , but not other products of mevalonate metabolism, activated LXR at concentrations consistent with those found in tissue extracts. In contrast, GG-PP, another metabolite of MVA, was a strong inhibitor of LXR. LXR binds as a heterodimer with the retinoid-X-receptor (RXR) to DENA response elements that are direct repeats of the core sequence AG(G/T) TCA spaced by four nucleotides, a so-called DR-4 motif. Recently, it was found that two closely related LXR subfamily members exist, referred to as LXRα and LXRβ, which show very similar activation characteristics.
LXR response element in the t-PA promoter
A software-based search of the t-PA promoter for a binding site for RXR/LXR led to the identification of a putative response element at position -8,682: ACTGGG taac ACTTGG (motif DR4/inv) . A similar DR4 motif was shown to bind LXRα and LXRβ in series of gel retardation assays.
The sequence is part of a 2.4 kb DNA fragment, located 7.1 kb upstream relative to the start site of transcription, which acts as a multi-hormone enhancer.
Analysis of intermediates of the mevalonate pathway Procedures for the isolation and analysis of 11 intermediates of the mevalonate pathway from acetyl-CoA through geranylgeranyl -pyrophosphate were adapted from the literature (Anal. Biochem. 215, 141-149, 1993). Routinely, rapid suspension of the cells in neutral 7 M urea with subsequent freeze- lysing in liquid nitrogen was found to effectively extract the cells. Mg2+-dependent phosphohydrolases were inhibited by addition of EDTA. Extracts are partially purified by adsorption and desorption in high yield from an anion-exchange membrane. The pathway
intermediates are subsequently separated and quantified by reversed-phase ion-pair HPLC by examining the incorporation of [14C] pyruvate, [14C] mevalonate or [3H] -isopentenyl- pyrophosphate as precursors. Identification is primarily on the basis of established retention times. The addition of internal standards at the beginning of the extraction procedure allows the correction of any variability in recovery of the radio- labelled intermediates between experiments or between individual samples. The procedure is readily adaptable to cultured human endothelial cells.
Analysis of oxysterols
For the analysis of oxysterols, essentially the procedures described by the group of TA Spencer are used (J. Bioϊ. Chem. 260, 14571-14579, 1985; 262, 14056-14062, 1987). After incubation of cells with [3H] mevalonate, sterol fractions of the cells are isolated and prepared for HPLC utilising procedures designed to prevent aut -oxidation of sterols and acid-catalysed hydrolysis of epoxides . Again, the addition of internal standards allows calculation of recov-eries. Identification of the sterols will primarily be on the basis of HPLC retention times and co-chromatography with authentic samples, this procedure too is easily applicable to cultured mesothelial cells.
Cell incubations and incubation variables Throughout many experiments charcoal -treated or thoroughly extracted serum are used to remove sterols, hormones and lipids. In experiments where it is essential to deprive cells of exogenous cholesterol (to prevent oxysterol formation from existing cholesterol), cells are pre-treated with lipoprotein-depleted serum. Where appropriate both media and cells are collected for analysis.
Cells are compared for their mevalonate metabolites and sterols to evaluate differences.
In parallel, t-PA, u-PA, PAI-1 are measured to obtain information regarding the intracellular metabolic processes
19
("the isoprenoid balance") and the expression of markers of mesothelial functioning. Antigen measurements are performed using routine methods such as ELISA.
Example 1 One way to increase t-PA synthesis by mesothelial cells is to prevent the mtracellular synthesis of mevalonic acid (MVA) from 3-hydroxy-3 -methylglutaryl coenzyme A (HMG-CoA) , for example, by the administration of simvastatin, an inhibitor of HMG-CoA reductase (Goldstein and Brown, Nature 343, 425, 1990) .
The results shown m Figure 1 demonstrate that addition of simvastatin (1 μmol/L) increased t-PA levels m 24 hours-conditioned medium from 64 ng/ml under control concfϊtions to 199 ng/ml the presence of simvastatin. Co- administration of mevalonate (10 μmol/L) or geranylgeraniol (10 μmol/L) , compounds which by themselves had little effect on t-PA synthesis, largely counteracted the t-PA synthesis stimulating effect of simvastatin.
Example 2 We measured t-PA antigen accumulation m the conditioned media of mesothelial cells after 24 hours incubation the presence of simvastatin (1 μmol/L) , 22 (R) -hydroxycholesterol (10 μmol) or a combination thereof (Fig. 2) . Both compounds increased t-PA antigen production and, when added together, showed at least additive effects.
Example 3
To check whether inhibition of mtracellular MVA synthesis also increases t-PA synthesis m cells other than mesothelial cells, we measured t-PA antigen accumulation the conditioned media of endothelial cells after 24 hours incubation m the presence of simvastatin (1 μmol/L) . We found that simvastatin increased t-PA levels to 6.7 ng/ml as compared to 2.8 ng/ml under control conditions (Fig. 3) . The effect of simvastatin was further potentiated by the
20
simultaneous additionof 9-cis retinoic acid (10 μmol/L) and 22 (R) -hydroxycholesterol (10 μmol/L).
Example 4
To check whether the stimulating effect of simvastatin on t-PA synthesis in MEC and HEC is not the result of a general effect on protein synthesis in these cells, we also measured a specific inhibitor of t-PA, PAI-1. The addition of simvastatin (1 μmol/L) to MEC and HEC significantly reduced PAI-1 levels in 24 hours conditioned medium, as shown in Fig. 4.
Claims
1. A method for reducing or preventing adhesions to or between organs, parts of organs or tissues, at a particular location, in an animal, comprising subjecting said animal to a treatment which provides for increased synthesis and/or secretion of plasminogen activator or for decreased synthesis and/or secretion of plasminogen activator inhibitor by mesothelial cells present at said location. *
2. A method according to claim 1 further comprising increasing endogenous fibrinolytic capacity at said location.
3. _method according to claim 1 or 2 wherein said animal is a mammal .
4. A method according to claim 23wherein said mammal is a human being.
5. A method according to any of claims 1 to 4 wherein said location is, has been or may be exposed to trauma, which might lead to local fibrosis.
6. -A method according to any of claims 1 to 5 wherein said trauma is a surgical procedure, e.g. abdominal or thoracic surgery.
7. A method according to any of claims 1 to 6 wherein said treatment comprises administration to said animal of an active agent capable of increasing plasminogen activator synthesis and/or secretion by said mesothelial cells.
8. A method according to claim 7 wherein said active agent is capable of increasing t-PA synthesis and/or secretion.
9. A method according to claim 7 or 8 wherein said active agent is selected from the group composed of vastatins such as simvastatin, lovastatin, mevinoline, or distinct oxysterols such as 22 (R) -hydroxycholesterol .
10. A method according to claim 7 or 8 wherein said active agent is capable of inhibiting HMG-CoA reductase or capable of activating liver-X-receptor. 22
11. A method according to any of claims 1 to 6 wherein said treatment comprises administration to said animal of an active agent capable of decreasing plasminogen activator inhibitor synthesis and/or secretion by said mesothelial cells.
12. A method according to claim 11 wherein said active agent is capable of decreasing PAI-1 synthesis and/or secretion.
13. A method according to claim 11 or 12 wherein said active agent is selected from the group composed of vastatins such as simvastatin, lovastatin, mevinoline.
14. A method which counteracts or mitigates' a method according to any of claims 1 to 13 comprising subjecting said animal to a treatment with an active agent, said agent preferably being MVA or geranylgeraniol .
15. Use of an active agent capable of providing for increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor by mesothelial cells, for preparing a pharmaceutical composition for reducing or preventing adhesions to or between organs, parts of organs or tissues.
16.- Use according to claim 15, wherein said mesothelial cells are mammalian, preferably human.
17. Use according to claim 15 or 16 wherein said active agent is capable of enhancing synthesis and/or secretion of plasminogen activator, preferably of t-PA.
18. Use according to claim 15 or 16 wherein said active agent is capable of decreasing synthesis and/or secretion of plasminogen activator inhibitor, preferably of PAI-1.
19. Use according to claim 17 or 18 wherein said active agent is selected from the group composed of vastatins or distinct natural oxysterols, and optionally combined with retinoic acid.
20. Use according to claim 17 or 18 wherein said active agent is capable of inhibiting HMG-CoA reductase or capable of activating liver-X-receptor. 23
21. Use of an active agent capable of controlling increased synthesis and/or secretion of plasminogen activator or decreased synthesis and/or secretion of plasminogen activator inhibitor in mesothelial cells, for preparing a pharmaceutical composition for counteracting or mitigating a method according to any of claims 1 to 13.
22. Use according to claim 21 wherein said active agent is MVA or geranylgeraniol .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99910880A EP1063989A1 (en) | 1998-03-19 | 1999-03-19 | Prevention and treatment of adhesions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98200893 | 1998-03-19 | ||
EP98200893A EP0943332A1 (en) | 1998-03-19 | 1998-03-19 | Prevention and treatment of adhesions |
PCT/NL1999/000157 WO1999047136A1 (en) | 1998-03-19 | 1999-03-19 | Prevention and treatment of adhesions |
EP99910880A EP1063989A1 (en) | 1998-03-19 | 1999-03-19 | Prevention and treatment of adhesions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1063989A1 true EP1063989A1 (en) | 2001-01-03 |
Family
ID=8233495
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98200893A Withdrawn EP0943332A1 (en) | 1998-03-19 | 1998-03-19 | Prevention and treatment of adhesions |
EP99910880A Withdrawn EP1063989A1 (en) | 1998-03-19 | 1999-03-19 | Prevention and treatment of adhesions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98200893A Withdrawn EP0943332A1 (en) | 1998-03-19 | 1998-03-19 | Prevention and treatment of adhesions |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP0943332A1 (en) |
JP (1) | JP2002506817A (en) |
AU (1) | AU2964199A (en) |
WO (1) | WO1999047136A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1556057A4 (en) * | 2002-08-29 | 2009-07-15 | Univ California | Agents and methods for enhancing bone formation |
US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
EP1993558B1 (en) | 2006-02-27 | 2014-07-30 | The Regents of The University of California | Oxysterol compounds and the hedgehog pathway |
AU2008331808B2 (en) | 2007-03-16 | 2014-08-21 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
CA2872751A1 (en) | 2012-05-07 | 2013-11-14 | The Regents Of The University Of California | Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
CN105263500A (en) | 2013-05-02 | 2016-01-20 | 加利福尼亚大学董事会 | Bone-selective osteogenic oxysterol-bone targeting agents |
CN111019850B (en) * | 2019-10-21 | 2022-11-08 | 武汉合生科技有限公司 | Recombinant microorganism, construction method and method for obtaining alpha-farnesene |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU586306B2 (en) * | 1985-12-16 | 1989-07-06 | Ethicon Inc. | Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator |
EP0563280B1 (en) * | 1990-12-18 | 1994-11-17 | Genentech, Inc. | Tissue plasminogen activator substitution variant |
US5633285A (en) * | 1991-03-01 | 1997-05-27 | Warner-Lambert Company | Cytoprotective wound healing compositions and methods for preparing and using same |
-
1998
- 1998-03-19 EP EP98200893A patent/EP0943332A1/en not_active Withdrawn
-
1999
- 1999-03-19 AU AU29641/99A patent/AU2964199A/en not_active Abandoned
- 1999-03-19 JP JP2000536376A patent/JP2002506817A/en active Pending
- 1999-03-19 EP EP99910880A patent/EP1063989A1/en not_active Withdrawn
- 1999-03-19 WO PCT/NL1999/000157 patent/WO1999047136A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9947136A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0943332A1 (en) | 1999-09-22 |
WO1999047136A1 (en) | 1999-09-23 |
JP2002506817A (en) | 2002-03-05 |
AU2964199A (en) | 1999-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tobert | New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. | |
US6140364A (en) | Arachidonic acid metabolite, 16-HETE | |
CA2489702A1 (en) | Novel anticholesterol compositions and method for using same | |
CA2614885C (en) | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | |
US20110288134A1 (en) | Composition and method for treating fibrosis | |
JPH01311030A (en) | Angiogenesis inhibiting collagen metabolism control drug | |
WO2010033637A1 (en) | Dissolution of arterial plaque | |
CA2700585A1 (en) | Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders | |
EP0943332A1 (en) | Prevention and treatment of adhesions | |
EP2978408B1 (en) | Pharmaceutical formulation for use in the treatment and/or prevention of restenosis | |
EP0651637B1 (en) | Control of wound scar production with calmodulin inhibitors or protein kinase c inhibitors | |
JP2003513913A (en) | Method of treating, inhibiting or preventing pathological changes caused by vascular injury with aldosterone antagonists | |
Martínez‐González et al. | Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model | |
EP2192904B1 (en) | METHODS FOR INHIBITING TGF-beta | |
Turpie | Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice | |
Li et al. | Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits | |
US20110091552A1 (en) | Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions | |
WO2004112837A1 (en) | PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR | |
EP2737904A2 (en) | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury | |
Hoscan* et al. | Oral fluvastatin reduces the severity of peritoneal adhesions in rats | |
US11744821B2 (en) | Compositions and methods for treating defects in avascular cartilaginous tissue by directly administering one or more metabolites of simvastatin | |
EP3290022B1 (en) | Use of statins in the treatment of ischemic diseases | |
EP1448184B1 (en) | Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie s disease | |
Haynes Jr | Hormonal drugs | |
EP4360619A1 (en) | Dosage form for intra-articular injection comprising colchicine and an anesthesic agent in the treatment of crystal-and non-crystal associated acute inflammatory arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001018 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020307 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050330 |